Veit, Guido, Dreano, Elise, Avramescu, Radu, Bagdany, Miklos, Beitel, Lenore, Roldan, Ariel, Hancock, Mark, Lay, Cecilia, Li, Wei, Morin, Katie, Gao, Sandra, Puiying, Mak, Ainscow, Edward, Orth, Anthony, McNamara, Peter, Edelman, Aleksander, Frenkiel, Saul, Matouk, Elias, Sermet-Gaudelus, Isabelle, Barnes, William and Lukacs, Gergely (2018) Structure-guided combination therapy to potently improve the function of mutant CFTRs. Nature Medicine.

Abstract

Available drugs are unable to effectively rescue the folding defects in vitro and ameliorate the clinical-phenotype of cystic fibrosis (CF), caused by deletion of F508 (ΔF508 or F508del) and some point mutations in the CF transmembrane conductance regulator (CFTR), a plasma membrane (PM) anion channel. To overcome the corrector efficacy ceiling, here we show that compounds targeting distinct structural defects of CFTR can synergistically rescue mutants expression and function at the PM. High throughput cell-based screens and mechanistic analysis identified three small-molecule series that target defects at the nucleotide binding domain (NBD1), NBD2 and their membrane spanning domains (MSDs) interfaces. While individually these compounds marginally improve ΔF508-CFTR folding efficiency, function, and stability, their combinations lead to ~50-100% of wild type-level correction in immortalized and primary human airway epithelia, and in mouse nasal epithelia. Likewise, corrector combinations were effective for rare missense mutations in various CFTR domains, probably acting via structural allostery, suggesting a mechanistic framework for their broad application.

Item Type:	Article
Date Deposited:	30 Oct 2018 00:45
Last Modified:	30 Oct 2018 00:45
URI:	https://oak.novartis.com/id/eprint/37480